Explore our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts.
The 5th Annual Psychedelic Therapeutics and Drug Development Conference brings together industry leaders, researchers, and investors to explore the latest advancements in psychedelic medicine. Join us to discuss clinical trials, regulatory updates, emerging therapies, and commercialization strategies shaping the future of psychedelic drug development.
Pα+ Psychedelic Bulletin #194
Pα+ Psychedelic Bulletin #193
Psychedelic Policy Update: Medical Access, Industry Influence, and Voter Suppression Shape 2025 Landscape
The 5th Annual Psychedelic Therapeutics and Drug Development Conference brings together industry leaders, researchers, and investors to explore the latest advancements in psychedelic medicine. Join us to discuss clinical trials, regulatory updates, emerging therapies, and commercialization strategies shaping the future of psychedelic drug development.
Transcend Therapeutics has shared topline results from its Phase 2 study of the MDMA analog methylone (TSND-201) in PTSD. While the readout is certainly positive, questions remain about the intervention’s scalability, specifics around the protocol, and the company’s IP moat. Read more…
See also a Research Briefing on the article.
Yesterday, Representatives Lou Correa (D) and Jack Bergman (R) introduced the Innovative Therapies Centers of Excellence Act. The bipartisan bill—co-sponsored by Reps. Morgan Luttrell (R), Ro Khanna (D), and Dan Crenshaw (R)—would see the VA designate at least five such centres, which would focus on researching and delivering certain psychedelic therapies. Here, we speak to two of the bill’s architects…
Free subscribers receive a weekly round-up of news on psychedelics, as well as the occasional article.
Receive regular bulletins, articles, interviews with insiders and quick-take analysis of major stories and developments.
Teams, groups and corporate pricing plans are available, please get in touch via email to learn more.
Front-row access to the psychedelics space: breaking bulletins, in-depth articles, insider interviews and sharp analysis of the moments that matter—from major trial results and funding rounds to policy shifts shaping the future. Plus, full access to our complete archive and Library.
Learn More| Free | ||
|---|---|---|
| Weekly Psychedelic News Feed | ||
| Occasional Articles & Free Resources | ||
| Psychedelic Bulletins (In-Depth Briefings, Multiple per Month) | ||
| Quick-Take Analysis of Major Developments | ||
| In-Depth Articles & Deep Dives | ||
| Exclusive Interviews with Insiders & KOLs | ||
| Quarterly Video Briefings | ||
| Exclusive Tools & Data Resources | ||
| Library of Primers & Explainers | ||
|
Subscribe Now |
||
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
By signing up, you agree to our privacy policy. You can unsubscribe at any time.
Aside from group pricing, we also offer bespoke reports and regular briefings. Get in touch to discuss.